These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
373 related items for PubMed ID: 19047164
1. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I. Cancer Res; 2008 Dec 01; 68(23):9839-44. PubMed ID: 19047164 [Abstract] [Full Text] [Related]
2. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, Leamon CP. Cancer Res; 2007 Jul 01; 67(13):6376-82. PubMed ID: 17616697 [Abstract] [Full Text] [Related]
3. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, Westrick E, Klein PJ, Wang Y, Vlahov IR, Leamon CP. Mol Pharm; 2009 Jul 01; 6(5):1518-25. PubMed ID: 19630399 [Abstract] [Full Text] [Related]
4. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model. Arote RB, Hwang SK, Lim HT, Kim TH, Jere D, Jiang HL, Kim YK, Cho MH, Cho CS. Biomaterials; 2010 Mar 01; 31(8):2435-45. PubMed ID: 20022105 [Abstract] [Full Text] [Related]
5. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S. Cancer Chemother Pharmacol; 2010 May 01; 66(1):43-52. PubMed ID: 19779718 [Abstract] [Full Text] [Related]
6. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy. Leamon CP, Reddy JA, Vlahov IR, Dorton R, Bloomfield A, Vetzel M, Klein PJ, Westrick E, Xu LC, Wang Y. Cancer Chemother Pharmacol; 2017 Jun 01; 79(6):1151-1160. PubMed ID: 28451831 [Abstract] [Full Text] [Related]
7. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP. Cancer Res; 2007 May 01; 67(9):4434-42. PubMed ID: 17483358 [Abstract] [Full Text] [Related]
8. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates. Leamon CP, Reddy JA, Dorton R, Bloomfield A, Emsweller K, Parker N, Westrick E. J Pharmacol Exp Ther; 2008 Dec 01; 327(3):918-25. PubMed ID: 18791065 [Abstract] [Full Text] [Related]
9. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential. Lu Y, You F, Vlahov I, Westrick E, Fan M, Low PS, Leamon CP. Mol Pharm; 2007 Dec 01; 4(5):695-706. PubMed ID: 17784727 [Abstract] [Full Text] [Related]
10. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors. Müller C, Schubiger PA, Schibli R. Nucl Med Biol; 2007 Aug 01; 34(6):595-601. PubMed ID: 17707798 [Abstract] [Full Text] [Related]
11. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative. Ross TL, Honer M, Lam PY, Mindt TL, Groehn V, Schibli R, Schubiger PA, Ametamey SM. Bioconjug Chem; 2008 Dec 01; 19(12):2462-70. PubMed ID: 19053298 [Abstract] [Full Text] [Related]
13. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M, Westrick E. Bioconjug Chem; 2006 Apr 29; 17(5):1226-32. PubMed ID: 16984132 [Abstract] [Full Text] [Related]
14. [Folate receptor-mediated antitumor drugs]. Zhao J, Cao SL, Zheng XL, Zhao B. Yao Xue Xue Bao; 2009 Feb 29; 44(2):109-14. PubMed ID: 19408677 [Abstract] [Full Text] [Related]
15. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL. Cancer Res; 2005 Dec 15; 65(24):11721-8. PubMed ID: 16357184 [Abstract] [Full Text] [Related]
16. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Leamon CP, Reddy JA, Vlahov IR, Vetzel M, Parker N, Nicoson JS, Xu LC, Westrick E. Bioconjug Chem; 2005 Dec 15; 16(4):803-11. PubMed ID: 16029021 [Abstract] [Full Text] [Related]
17. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Leamon CP, Cooper SR, Hardee GE. Bioconjug Chem; 2003 Dec 15; 14(4):738-47. PubMed ID: 12862426 [Abstract] [Full Text] [Related]
18. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice. Müller C, Reddy JA, Leamon CP, Schibli R. Mol Pharm; 2010 Apr 05; 7(2):597-604. PubMed ID: 20199053 [Abstract] [Full Text] [Related]
19. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Eur J Pharm Biopharm; 2008 Nov 05; 70(3):718-25. PubMed ID: 18647651 [Abstract] [Full Text] [Related]
20. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP. Cancer Chemother Pharmacol; 2006 Aug 05; 58(2):229-36. PubMed ID: 16331500 [Abstract] [Full Text] [Related] Page: [Next] [New Search]